These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 25357001)

  • 21. Integrated Application of Quality-by-Design Principles to Drug Product Development: A Case Study of Brivanib Alaninate Film-Coated Tablets.
    Badawy SI; Narang AS; LaMarche KR; Subramanian GA; Varia SA; Lin J; Stevens T; Shah PA
    J Pharm Sci; 2016 Jan; 105(1):168-81. PubMed ID: 26852852
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Scientific, statistical, practical, and regulatory considerations in design space development.
    Debevec V; Srčič S; Horvat M
    Drug Dev Ind Pharm; 2018 Mar; 44(3):349-364. PubMed ID: 29200316
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A Process Analytical Technology (PAT) approach to control a new API manufacturing process: development, validation and implementation.
    Schaefer C; Clicq D; Lecomte C; Merschaert A; Norrant E; Fotiadu F
    Talanta; 2014 Mar; 120():114-25. PubMed ID: 24468350
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Process analytical technology in the pharmaceutical industry: a toolkit for continuous improvement.
    Scott B; Wilcock A
    PDA J Pharm Sci Technol; 2006; 60(1):17-53. PubMed ID: 17089677
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lyophilization process design space.
    Patel SM; Pikal MJ
    J Pharm Sci; 2013 Nov; 102(11):3883-7. PubMed ID: 23946165
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Experimental designs and their recent advances in set-up, data interpretation, and analytical applications.
    Dejaegher B; Heyden YV
    J Pharm Biomed Anal; 2011 Sep; 56(2):141-58. PubMed ID: 21632194
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The central role of chemistry in 'quality by design' approaches to drug development.
    Grewal NK; Leadbeater NE
    Future Med Chem; 2012 Sep; 4(14):1799-810. PubMed ID: 23043477
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A Generalized Pivotal Quantity Approach to Analytical Method Validation Based on Total Error.
    Yang H; Zhang J
    PDA J Pharm Sci Technol; 2015; 69(6):725-35. PubMed ID: 26659103
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Strategic funding priorities in the pharmaceutical sciences allied to Quality by Design (QbD) and Process Analytical Technology (PAT).
    Aksu B; De Beer T; Folestad S; Ketolainen J; Lindén H; Lopes JA; de Matas M; Oostra W; Rantanen J; Weimer M
    Eur J Pharm Sci; 2012 Sep; 47(2):402-5. PubMed ID: 22749874
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Quality cell therapy manufacturing by design.
    Lipsitz YY; Timmins NE; Zandstra PW
    Nat Biotechnol; 2016 Apr; 34(4):393-400. PubMed ID: 27054995
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmaceutical quality by design: product and process development, understanding, and control.
    Yu LX
    Pharm Res; 2008 Apr; 25(4):781-91. PubMed ID: 18185986
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prevalidation in pharmaceutical analysis. Part I. Fundamentals and critical discussion.
    Grdinić V; Vuković J
    J Pharm Biomed Anal; 2004 May; 35(3):489-512. PubMed ID: 15137975
    [TBL] [Abstract][Full Text] [Related]  

  • 33. System-wide hybrid MPC-PID control of a continuous pharmaceutical tablet manufacturing process via direct compaction.
    Singh R; Ierapetritou M; Ramachandran R
    Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):1164-82. PubMed ID: 23523542
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Quality by design approach for formulation development: a case study of dispersible tablets.
    Charoo NA; Shamsher AA; Zidan AS; Rahman Z
    Int J Pharm; 2012 Feb; 423(2):167-78. PubMed ID: 22209997
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Application of quality by design and statistical quality control concepts in immunoassays.
    Verch T
    Bioanalysis; 2014; 6(23):3251-60. PubMed ID: 25529891
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Rapid exploration of curing process design space for production of controlled-release pellets.
    Kristan K; Horvat M
    J Pharm Sci; 2012 Oct; 101(10):3924-35. PubMed ID: 22833184
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Multivariate PAT solutions for biopharmaceutical cultivation: current progress and limitations.
    Mercier SM; Diepenbroek B; Wijffels RH; Streefland M
    Trends Biotechnol; 2014 Jun; 32(6):329-36. PubMed ID: 24732022
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Development, validation and transfer of a near infrared method to determine in-line the end point of a fluidised drying process for commercial production batches of an approved oral solid dose pharmaceutical product.
    Peinado A; Hammond J; Scott A
    J Pharm Biomed Anal; 2011 Jan; 54(1):13-20. PubMed ID: 20801599
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Transfer of analytical procedures: a panel of strategies selected for risk management, with emphasis on an integrated equivalence-based comparative testing approach.
    Agut C; Caron A; Giordano C; Hoffman D; Ségalini A
    J Pharm Biomed Anal; 2011 Sep; 56(2):293-303. PubMed ID: 21700410
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A quality by design (QbD) case study on liposomes containing hydrophilic API: II. Screening of critical variables, and establishment of design space at laboratory scale.
    Xu X; Khan MA; Burgess DJ
    Int J Pharm; 2012 Feb; 423(2):543-53. PubMed ID: 22155413
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.